Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

BACKGROUND: Erlotinib is a drug used for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Severe hepatotoxicity was observed in 4% to 31% of patients receiving erlotinib treatment prompting delay or termination of treatment. Only a few factors related to hepatotoxicity of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Min Kyoung, Yee, Jeong, Cho, Yoon Sook, Jang, Hong Won, Han, Ji Min, Gwak, Hye Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191908/
https://www.ncbi.nlm.nih.gov/pubmed/30326853
http://dx.doi.org/10.1186/s12885-018-4891-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191908/
https://www.ncbi.nlm.nih.gov/pubmed/30326853
http://dx.doi.org/10.1186/s12885-018-4891-7

Ejemplares similares